Immune myocarditis related to sintilimab treatment in a patient with advanced lung adenocarcinoma: A case report

Immune checkpoint inhibitors (ICI) have improved clinical outcomes of patients with advanced lung cancer, but may lead to fatal cardiac injury. We describe a 66-year-old man with advanced lung adenocarcinoma who presented with chest pain and dyspnea 3 weeks after the first dose of sintilimab. The in...

Descripción completa

Detalles Bibliográficos
Autores principales: Lin, Yunling, Yuan, Xun, Chen, Lianglong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Cardiovascular Medicine
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9582520/
https://www.ncbi.nlm.nih.gov/pubmed/36277753
http://dx.doi.org/10.3389/fcvm.2022.955527

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9582520/
https://www.ncbi.nlm.nih.gov/pubmed/36277753
http://dx.doi.org/10.3389/fcvm.2022.955527

Ejemplares similares